A carregar...
Adding chimeric antigen receptor–induced killer cells to the medical oncology shelf
With the approval of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatment of B cell malignancies, clinicians have gained valuable insights into the power and challenges of cellular therapies. In this issue of the JCI, Maluski et al. showed that a CAR containing a CD28 costimulator...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6877296/ https://ncbi.nlm.nih.gov/pubmed/31638599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI132536 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|